Q3 2025 · 13F-HR
Foresite Capital Management VI LLCholdings as filed
Filed 2025-11-14 · accession 0001104659-25-112509
$258.9M
Reported value
12
Positions
2025-09-30
Period end
The Brief · Foresite Capital Management VI LLC · Q3 2025
AI · grounded in 13F
Foresite Capital Management VI LLC established a new position in CG Oncology, Inc. CGON valued at $89.5M. The fund also initiated new stakes in RAPT Therapeutics, Inc. RAPT for $40.3M and Centessa Pharmaceuticals plc CNTA for $31.9M. Additional new positions include Verastem, Inc. VSTM, ALUMIS INC. ALMS, and Denali Therapeutics Inc. DNLI.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG Oncology, Inc. | $89.5M | 34.6% | 2,221,474 | Common | SOLE |
| 75382E208 | RAPT | RAPT Therapeutics, Inc. | $40.3M | 15.6% | 1,562,500 | Common | SOLE |
| 152309100 | CNTA | Centessa Pharmaceuticals plc | $31.9M | 12.3% | 1,314,019 | Common | SOLE |
| 92337C203 | VSTM | Verastem, Inc. | $23.1M | 8.92% | 2,615,120 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC. | $16.9M | 6.55% | 4,247,670 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc. | $14.5M | 5.61% | 1,000,000 | Common | SOLE |
| 221015100 | CRVS | Corvus Pharmaceuticals, Inc. | $12.8M | 4.93% | 1,731,233 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics, Inc. | $11.6M | 4.49% | 244,900 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $8.3M | 3.20% | 146,332 | Common | SOLE |
| 433313103 | HNGE | Hinge Health, Inc. | $6.6M | 2.56% | 135,000 | Common | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences, Inc. | $1.7M | 0.67% | 40,000 | Common | SOLE |
| G1933S101 | CASIF | CASI Pharmaceuticals, Inc. | $1.6M | 0.63% | 979,956 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.